ALW-II-41-27

ALW-II-41-27

CAT N°: 25275
Price:

From 92.00 78.20

ALW-II-41-27 is a multi-kinase inhibitor that inhibits EphB2, EphA3, Kit, FMS, VEGFR2/KDR, FLT1, FGR, Src, Lyn, BMX, and Bcr-Abl in tyrosine kinase-transformed Ba/F3 cells (EC50s = 50s = 51 and 14 nM, respectively) as well as wild-type and mutant RET kinases (IC50s = 24.7, 94.2, and 15.8 nM for wild-type, RETV804L, and RETV804M, respectively).{39848,39849} It reduces growth of NCI-H2286 and HCC-366 cancer cells (GI50s = 0.51 and 0.65 ?M, respectively) and RAT1 cells transformed by RETC634R or RETM918T (IC50s = 44 and 56 nM, respectively). ALW-II-41-27 also inhibits growth of MDA-MB-231 breast cancer cells in a concentration-dependent manner and inhibits tumor growth in vivo in a mouse patient-derived xenograft (PDX) model of EphA2-overexpressing triple-negative breast cancer (TNBC).{39850}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[[[5-(2-thienyl)-3-pyridinyl]carbonyl]amino]-benzamide
  • Correlated keywords
    • ALWII4127 ALWII41 ALWII-4127 EphB-2 EphA-3 2 Eph-B2 A2 A3 VEGFR-2 FLT-1 BaF3 F-3 DDR-2 H-2286 NCIH2286 HCC366 RAT-1 MDAMB231 MB231 MDAMB multikinase CSF1R
  • Product Overview:
    ALW-II-41-27 is a multi-kinase inhibitor that inhibits EphB2, EphA3, Kit, FMS, VEGFR2/KDR, FLT1, FGR, Src, Lyn, BMX, and Bcr-Abl in tyrosine kinase-transformed Ba/F3 cells (EC50s = 50s = 51 and 14 nM, respectively) as well as wild-type and mutant RET kinases (IC50s = 24.7, 94.2, and 15.8 nM for wild-type, RETV804L, and RETV804M, respectively).{39848,39849} It reduces growth of NCI-H2286 and HCC-366 cancer cells (GI50s = 0.51 and 0.65 ?M, respectively) and RAT1 cells transformed by RETC634R or RETM918T (IC50s = 44 and 56 nM, respectively). ALW-II-41-27 also inhibits growth of MDA-MB-231 breast cancer cells in a concentration-dependent manner and inhibits tumor growth in vivo in a mouse patient-derived xenograft (PDX) model of EphA2-overexpressing triple-negative breast cancer (TNBC).{39850}

We also advise you